INSMED Inc
INSMED Inc (INSM): 83 pipeline candidates · 5 upcoming catalysts · ~18 mo cash runway · 66 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
17.6 months
D/E 1.95 · 0% dilution
Lead: Approved
83 candidates
5 upcoming, next in ~196d
0 buys · 109 sells (180d)
A transparent, data-derived signal for INSMED Incacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$21.1B
Cash
$582.2M
Quarterly Burn
$222.7M
Runway
17.6 mo
Revenue
$306.0M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (83 candidates)
| Drug | Phase |
|---|---|
| 280 mg Arikayce™ | Phase 2 |
| 560 mg Arikayce™ | Phase 2 |
| ALIS | Phase 3 |
| Amoxicillin | Phase 4 |
| Anakinra | N/A |
| ARIKACE™ | Phase 2 |
| ARIKAYCE | Approved |
| Arikayce™ | Phase 2 |
| Azithromycin | Phase 3 |
| AZM Group | Phase 3 |
Showing 10 of 83 candidates. Sign up for full pipeline.
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
667
Total value held
$27.76B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 19,284,262 | $3.15B |
| blackrock, inc. | 16,678,146 | $2.73B |
| fmr llc | 13,160,167 | $2.15B |
| vanguard portfolio management llc | 10,371,802 | $1.70B |
| baker bros. advisors lp | 7,421,111 | $1.21B |
| d. e. shaw & co., inc. | 5,642,725 | $922.7M |
| state street corp | 5,551,699 | $907.8M |
| rtw investments, lp | 4,842,880 | $791.9M |
| geode capital management, llc | 4,450,389 | $733.3M |
| ameriprise financial inc | 3,057,718 | $500.0M |
Showing top 10 of 667 institutional holders of INSMED Inc. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in INSMED Inc's pipeline?
INSMED Inc (INSM) has 83 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is INSMED Inc's lead drug candidate?
INSMED Inc's most advanced tracked candidate is 280 mg Arikayce™ (Phase 2) for Bronchiectasis.
What is INSMED Inc's next catalyst?
INSMED Inc's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term" — expected December 31, 2026.
What is INSMED Inc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, INSMED Inc has approximately 17.6 months of cash runway.
What is INSMED Inc's market capitalization?
INSMED Inc's market capitalization is approximately $21.1B.
Get the full picture on INSMED Inc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.